{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:56:41Z","timestamp":1791107801284,"version":"4.1.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To test whether canrenone, an aldosterone receptor antagonist, improves left ventricular (LV) remodelling in NYHA class II heart failure (HF). Aldosterone receptor antagonists improve outcome in severe HF, but no information is available in NYHA class II.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>AREA IN-CHF is a randomized, double-blind, placebo-controlled study testing canrenone on top of optimal treatment in NYHA class II HF with low ejection fraction (EF) to assess 12-month changes in LV end-diastolic volume (LVEDV). Brain natriuretic peptide (BNP) was also measured. Information was available for 188 subjects on canrenone and 194 on placebo. Left ventricular end-diastolic volume was similarly reduced (\u221218%) in both arms, but EF increased more (P = 0.04) in the canrenone (from 40% to 45%) than in the placebo arm (from 40\u201343%). Brain natriuretic peptide (n = 331) decreased more in the canrenone (\u221237%) than in the placebo arm (\u22128%; P &amp;lt; 0.0001), paralleling a significant reduction in left atrial dimensions (\u22124% vs. 0.2%; P = 0.02). The composite endpoint of cardiac death and hospitalization was significantly lower in the canrenone arm (8% vs. 15%; P = 0.02).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Canrenone on top of optimal treatment for HF did not have additional effects on LVEDV, but it increased EF, and reduced left atrial size and circulating BNP, with potential beneficial effects on outcome. A large-scale randomized study should be implemented to confirm benefits on cardiovascular outcomes in patients with HF in NYHA class II.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjhf\/hfn015","type":"journal-article","created":{"date-parts":[[2009,1,23]],"date-time":"2009-01-23T11:48:10Z","timestamp":1232711290000},"page":"68-76","source":"Crossref","is-referenced-by-count":105,"title":["Anti-Remodelling Effect of Canrenone in Patients with Mild Chronic Heart Failure (AREA IN-CHF study): Final Results"],"prefix":"10.1093","volume":"11","author":[{"given":"Alessandro","family":"Boccanelli","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Diseases, San Giovanni-Addolorata Hospital , Roma ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Francesco","family":"Mureddu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, San Giovanni-Addolorata Hospital , Roma ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cacciatore","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, San Giovanni-Addolorata Hospital , Roma ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Clemenza","sequence":"additional","affiliation":[{"name":"Heart Failure Unit, ISMETT , Palermo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Di Lenarda","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Azienda Ospedali Riuniti , Trieste ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Gavazzi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Azienda Ospedali Riuniti , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Porcu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Azienda G. Brotzu\u2014S. Michele , Cagliari ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Latini","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Research, Istituto Mario Negri , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donata","family":"Lucci","sequence":"additional","affiliation":[{"name":"ANMCO Research Center, Via A. La Marmora 34 , 50121, Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo Pietro","family":"Maggioni","sequence":"additional","affiliation":[{"name":"ANMCO Research Center, Via A. La Marmora 34 , 50121, Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Masson","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Research, Istituto Mario Negri , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Vanasia","sequence":"additional","affiliation":[{"name":"Therabel GiEnne Pharma SpA , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"de Simone","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Federico II University Hospital , Napoli ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,1,23]]},"reference":[{"key":"2026020203394089300_ejhfhfn015-bib-0001","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0735-1097(92)90167-L","article-title":"The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure","volume":"20","author":"Packer","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"2026020203394089300_ejhfhfn015-bib-0002","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/0002-9149(82)90243-0","article-title":"Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure","volume":"49","author":"Levine","year":"1982","journal-title":"Am J Cardiol"},{"key":"2026020203394089300_ejhfhfn015-bib-0003","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1161\/01.CIR.100.9.999","article-title":"Mechanisms and models in heart failure. A combinatorial approach","volume":"100","author":"Mann","year":"1999","journal-title":"Circulation"},{"key":"2026020203394089300_ejhfhfn015-bib-0004","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1023\/A:1015709617405","article-title":"Pathophysiologic and therapeutic importance of tissue ACE: a Consensus report","volume":"16","author":"Dzau","year":"2002","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026020203394089300_ejhfhfn015-bib-0005","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/0002-8703(89)90291-3","article-title":"The relationship of the sympathetic nervous system and the renin angiotensin system in congestive heart failure","volume":"118","author":"Francis","year":"1989","journal-title":"Am Heart J"},{"key":"2026020203394089300_ejhfhfn015-bib-0006","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/01.RES.84.4.417","article-title":"Regulation of sympathetic nerve activity in heart failure: a role for nitric oxide and angiotensin II","volume":"84","author":"Liu","year":"1999","journal-title":"Circ Res"},{"key":"2026020203394089300_ejhfhfn015-bib-0007","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0735-1097(99)00630-0","article-title":"Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling","volume":"35","author":"Cohn","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026020203394089300_ejhfhfn015-bib-0008","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/01.CIR.76.1.44","article-title":"Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction","volume":"76","author":"White","year":"1987","journal-title":"Circulation"},{"key":"2026020203394089300_ejhfhfn015-bib-0009","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM199705083361903","article-title":"Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction","volume":"336","author":"Vasan","year":"1997","journal-title":"N Engl J Med"},{"key":"2026020203394089300_ejhfhfn015-bib-0010","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"The SOLVD Investigators","year":"1992","journal-title":"N Engl J Med"},{"key":"2026020203394089300_ejhfhfn015-bib-0011","doi-asserted-by":"crossref","first-page":"907","DOI":"10.7326\/0003-4819-138-11-200306030-00012","article-title":"The epidemiology of \u2018asymptomatic\u2019 left ventricular systolic dysfunction: implications for screening","volume":"138","author":"Wang","year":"2003","journal-title":"Ann Intern Med"},{"key":"2026020203394089300_ejhfhfn015-bib-0012","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left ventricular ejection fraction. The CHARM-Preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"2026020203394089300_ejhfhfn015-bib-0013","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/eurheartj\/16.suppl_N.103","article-title":"Aldosterone escape during ACE inhibitor therapy in chronic heart failure","volume":"16","author":"Struthers","year":"1995","journal-title":"Eur Heart J"},{"key":"2026020203394089300_ejhfhfn015-bib-0014","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00877755","article-title":"\u2018Escape\u2019 of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy","volume":"9","author":"Pitt","year":"1995","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026020203394089300_ejhfhfn015-bib-0015","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0735-1097(01)01116-0","article-title":"Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure","volume":"37","author":"Tsutamoto","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"2026020203394089300_ejhfhfn015-bib-0016","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026020203394089300_ejhfhfn015-bib-0017","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with LV dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2026020203394089300_ejhfhfn015-bib-0018","first-page":"156","article-title":"ACC\/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society","volume":"20","author":"Hunt","year":"2005","journal-title":"Circulation"},{"key":"2026020203394089300_ejhfhfn015-bib-0019","first-page":"66S","article-title":"The AREA IN-CHF trial: antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure. Rationale and design","volume":"6","author":"Cacciatore","year":"2005","journal-title":"Ital Heart J"},{"key":"2026020203394089300_ejhfhfn015-bib-0020","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1053\/euhj.2001.2783","article-title":"Guidelines for the diagnosis and treatment of CHF","volume":"22","author":"Remme","year":"2001","journal-title":"Eur Heart J"},{"key":"2026020203394089300_ejhfhfn015-bib-0021","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2459\/JCM.0b013e3281053a9a","article-title":"Baseline characteristics of patients recruited in the AREA IN-CHF study (AntiRemodeling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure)","volume":"8","author":"Boccanelli","year":"2007","journal-title":"J Cardiovasc Med"},{"key":"2026020203394089300_ejhfhfn015-bib-0022","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1097\/00004872-200409000-00027","article-title":"Serial echocardiographic assessment of left ventricular mass: how blinded should readers be?","volume":"22","author":"Gosse","year":"2004","journal-title":"J Hypertens"},{"key":"2026020203394089300_ejhfhfn015-bib-0023","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0894-7317(89)80014-8","article-title":"Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms","volume":"2","author":"Schiller","year":"1989","journal-title":"J Am Soc Echocardiogr"},{"key":"2026020203394089300_ejhfhfn015-bib-0024","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0002-9149(86)90771-X","article-title":"Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings","volume":"57","author":"Devereux","year":"1986","journal-title":"Am J Cardiol"},{"key":"2026020203394089300_ejhfhfn015-bib-0025","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/0735-1097(92)90617-V","article-title":"Patterns of left ventricular hypertrophy and geometric remodelling in arterial hypertension","volume":"19","author":"Ganau","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"2026020203394089300_ejhfhfn015-bib-0026","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0735-1097(83)80200-9","article-title":"Left ventricular volumes determined by two-dimensional echocardiography in a normal adult population","volume":"1","author":"Wahr","year":"1983","journal-title":"J Am Coll Cardiol"},{"key":"2026020203394089300_ejhfhfn015-bib-0027","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0002-9149(96)00362-1","article-title":"Assessment of left ventricular function by meridional and circumferential end-systolic stress\/minor axis shortening relations in dilated cardiomyopathy","volume":"78","author":"Municin\u00f2","year":"1996","journal-title":"Am J Cardiol"},{"key":"2026020203394089300_ejhfhfn015-bib-0028","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1161\/01.CIR.78.1.68","article-title":"Correction for preload in assessment of myocardial contractility in aortic and mitral valve disease. Application of the concept of systolic myocardial stiffness","volume":"78","author":"Mirsky","year":"1988","journal-title":"Circulation"},{"key":"2026020203394089300_ejhfhfn015-bib-0029","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0894-7317(96)90136-4","article-title":"Doppler echocardiographic evaluation of left ventricular end-diastolic pressure in patients with coronary artery disease","volume":"9","author":"Cecconi","year":"1996","journal-title":"J Am Soc Echocardiogr"},{"key":"2026020203394089300_ejhfhfn015-bib-0030","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/0735-1097(93)90787-2","article-title":"Estimation of left ventricular filling pressures using two dimensional and Doppler echocardiography in adult patients with cardiac disease. Additional value of analyzing left atrial size, left atrial ejection fraction and the difference in duration of pulmonary venous and mitral flow velocity at atrial contraction","volume":"22","author":"Appleton","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"2026020203394089300_ejhfhfn015-bib-0031","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/01.CIR.0000036747.68104.AC","article-title":"Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure. The Valsartan Heart Failure Trial (Val-HeFT)","volume":"106","author":"Latini","year":"2002","journal-title":"Circulation"},{"key":"2026020203394089300_ejhfhfn015-bib-0032","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"2026020203394089300_ejhfhfn015-bib-0033","volume-title":"Heart Failure","author":"Zile","year":"2004"},{"key":"2026020203394089300_ejhfhfn015-bib-0034","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/jps.2600610719","article-title":"Fluorometric microassay for spironolactone and its metabolites in biological fluids","volume":"16","author":"Sad\u00e9e","year":"1972","journal-title":"J Pharm Sci"},{"key":"2026020203394089300_ejhfhfn015-bib-0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1067\/mhj.2001.111258","article-title":"Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction","volume":"141","author":"Modena","year":"2001","journal-title":"Am Heart J"},{"key":"2026020203394089300_ejhfhfn015-bib-0036","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0008-6363(03)00251-7","article-title":"Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure","volume":"58","author":"Cittadini","year":"2003","journal-title":"Cardiovasc Res"},{"key":"2026020203394089300_ejhfhfn015-bib-0037","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.euje.2007.02.005","article-title":"on behalf of the Action Investigators. Predictive value of local and core laboratory echocardiographic assessment of cardiac function in patients with chronic stable angina: The ACTION study","volume":"8","author":"Dart","year":"2007","journal-title":"Eur J Echocardiogr"},{"key":"2026020203394089300_ejhfhfn015-bib-0038","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.jacc.2004.09.038","article-title":"Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy","volume":"44","author":"Vanderheyden","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2026020203394089300_ejhfhfn015-bib-0039","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S1388-9842(00)00151-3","article-title":"Perceived benefit after participating in positive or negative\/neutral heart failure trials: the patients\u2019 perspective","volume":"3","author":"Yuval","year":"2001","journal-title":"Eur J Heart Fail"},{"key":"2026020203394089300_ejhfhfn015-bib-0040","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1097\/01.hjh.0000222768.15100.00","article-title":"The interplay between haemodynamic load, brain natriuretic peptide and left atrial size in the early stages of essential hypertension","volume":"24","author":"Tsioufis","year":"2006","journal-title":"J Hypertens"},{"key":"2026020203394089300_ejhfhfn015-bib-0041","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0735-1097(03)00956-2","article-title":"The left atrium: a biomarker of chronic diastolic dysfunction and cardiovascular disease risk","volume":"42","author":"Douglas","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026020203394089300_ejhfhfn015-bib-0042","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.jacc.2006.02.048","article-title":"Left atrial size: physiologic determinants and clinical applications","volume":"47","author":"Abhayaratna","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026020203394089300_ejhfhfn015-bib-0043","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jacc.2005.04.038","article-title":"Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure","volume":"46","author":"Pitt","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026020203394089300_ejhfhfn015-bib-0044","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0735-1097(02)01965-4","article-title":"Long term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure","volume":"40","author":"Cicoira","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026020203394089300_ejhfhfn015-bib-0045","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ejheart.2006.10.005","article-title":"Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker","volume":"9","author":"Berry","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"2026020203394089300_ejhfhfn015-bib-0046","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","article-title":"Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure","volume":"101","author":"Farquharson","year":"2000","journal-title":"Circulation"},{"key":"2026020203394089300_ejhfhfn015-bib-0047","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1161\/01.CIR.99.20.2694","article-title":"Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis","volume":"99","author":"Silvestre","year":"1999","journal-title":"Circulation"},{"key":"2026020203394089300_ejhfhfn015-bib-0048","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0002-8703(78)90052-2","article-title":"Spironolactone","volume":"96","author":"Ochs","year":"1978","journal-title":"Am Heart J"},{"key":"2026020203394089300_ejhfhfn015-bib-0049","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jchromb.2006.02.017","article-title":"Development and validation of an HPLC method for the determination of spironolactone and its metabolites in paediatric plasma samples","volume":"839","author":"Sandall","year":"2006","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2026020203394089300_ejhfhfn015-bib-0050","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1161\/CIRCULATIONAHA.106.670109","article-title":"Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death","volume":"115","author":"Pitt","year":"2007","journal-title":"Circulation"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfn015","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/11\/1\/68\/66547388\/eurjhf_11_1_68.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/11\/1\/68\/66547388\/eurjhf_11_1_68.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:39:58Z","timestamp":1770021598000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/11\/1\/68\/8439007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,1]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2009,1,23]]},"published-print":{"date-parts":[[2009,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjhf\/hfn015","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,1]]},"published":{"date-parts":[[2009,1,1]]}}}